<?xml version="1.0"?>
<DEBATE-SPEECH>
  <BILL>
    <TITLE> Medicinal products for paediatric use</TITLE>
    <CODE>A6-0247/2005</CODE>
    <DATE>2005-09-07</DATE>
    <ITEM>9</ITEM>
    <RAPPORTEUR>Françoise GROSSETETE</RAPPORTEUR>
    <ISSUEAREA>4</ISSUEAREA>
    <PASSED>1</PASSED>
    <RCV>0</RCV>
  </BILL>
  <SPEAKER>
    <NAME>President</NAME>
    <COUNTRY></COUNTRY>
    <GROUP></GROUP>
    <STATUS>
      <ISPRESIDENT>1</ISPRESIDENT>
      <ISCOUNCIL>0</ISCOUNCIL>
      <ISCOMMISSION>0</ISCOMMISSION>
      <ISOTHERBUREAUCRAT>0</ISOTHERBUREAUCRAT>
      <ISRAPPORTEUR>0</ISRAPPORTEUR>
      <ISCOMMITTEEREP>0</ISCOMMITTEEREP>
      <ISAUTHOR>0</ISAUTHOR>
      <ISONBEHALFOFGROUP>0</ISONBEHALFOFGROUP>
    </STATUS>
  </SPEAKER>
  <SPEAKER-NUMBER>34</SPEAKER-NUMBER>
  <TEXT>
    The debate is closed. The vote will take place tomorrow at 12 noon. Annex – Position of the Commission Grossetête report ( A6-0247/2005 )The Commission can accept the following amendments: 4, 5, 7, 10, 15 (1st part), 17, 18 (1st part), 19 (Art 2b, 1st part), 22 (1st part), 33, 34, 35, 39, 40 (deadline of 60 days, and 'or the request for a deferral or waiver'), 44 (1st part), 45, 46 (2nd part), 58, 62, 77, 80. The Commission can accept the following amendments in principle: 1, 2, 6 (1st part), 6 (3rd part), 8, 9, 19 (Art 2b, 2nd part [amp] Art 2c, 1st part), 20, 21, 22 (2nd part), 26, 27, 28, 31, 42, 43 (1st part [amp] 2nd part), 50, 52 (2nd part, re data protection), 55, 56, 57, 63, 64, 66, 67, 69, 76, 79. The Commission cannot accept the following amendments: 3, 6 (2nd part), 11, 12, 13, 14, 15 (2nd [amp] 3rd part), 16, 18 (2nd part), 19 (no to moving Articles), 19 (Art 2a, Art 2c 2nd part [amp] Art 2d), 23, 24, 25, 29, 30, 32, 36, 37, 38, 40 (last part), 41, 43 (3rd part), 44 (2nd part), 46 (1st [amp] 3rd parts), 47, 48, 49, 51, 52 (1st part, re patents), 53, 54, 59, 60, 61, 65, 68, 70, 71, 72, 73, 74, 75, 78, 81, 82, 83, 84, 85, 86, 87, 88, 89, 91, 92, 93.
  </TEXT>
</DEBATE-SPEECH>

